NasdaqCM - Nasdaq Real Time Price USD

Tivic Health Systems, Inc. (TIVC)

3.9400

-0.2100

(-5.06%)

At close: May 9 at 4:00:01 PM EDT

3.9900

+0.05

+(1.27%)

After hours: May 9 at 7:35:14 PM EDT

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

FREMONT, Calif., May 09, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET.

Business Wire yesterday

TIVC
-5.06%
Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

FREMONT, Calif., April 22, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th.

Business Wire 18 days ago

TIVC
-5.06%
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

FREMONT, Calif., April 15, 2025--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™.

Business Wire 25 days ago

TIVC
-5.06%
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

FREMONT, Calif., April 10, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health’s common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol "TIVC."

Business Wire 30 days ago

TIVC
-5.06%
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

FREMONT, Calif., March 21, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company’s operations.

Business Wire last month

TIVC
-5.06%
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

FREMONT, Calif., March 13, 2025--Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET.

Business Wire last month

TIVC
-5.06%
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

FREMONT, Calif., March 06, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation’s impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to cur

Business Wire 2 months ago

TIVC
-5.06%
Tivic Health Systems, Inc. Announces Reverse Stock Split

FREMONT, Calif., March 05, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC) ("Tivic Health" or the "Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company’s issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq"), and is part of the Co

Business Wire 2 months ago

TIVC
-5.06%
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve

FREMONT, Calif., March 03, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled "Method and Apparatus for Electrical Stimulation of the Vagus Nerve," expands the claims and protection around the technology in advance of potential U.S. Food & Drug

Business Wire 2 months ago

TIVC
-5.06%
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

FREMONT, Calif., February 24, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to dev

Business Wire 2 months ago

TIVC
-5.06%
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

FREMONT, Calif., February 12, 2025--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement esta

Business Wire 2 months ago

TIVC
-5.06%
CEO Letter to Shareholders Issued by Tivic Health

FREMONT, Calif., December 23, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders.

Business Wire 4 months ago

TIVC
-5.06%
Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Tivic Health Systems ( NASDAQ:TIVC ) Third Quarter 2024 Results Key Financial Results Revenue: US$126.0k (down 55% from...

Simply Wall St. 5 months ago

TIVC
-5.06%
Tivic hits enrolment target for vagus nerve stimulation trial

Tivic has not yet identified clinical targets as the company optimises its non-invasive technology.

Medical Device Network 5 months ago

TIVC
-5.06%
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

FREMONT, Calif., November 15, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology.

Business Wire 5 months ago

TIVC
-5.06%
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

FREMONT, Calif., November 14, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation (VNS) device.

Business Wire 5 months ago

TIVC
-5.06%
Tivic Health Validates European Patents in Great Britain, Germany, and France

FREMONT, Calif., November 12, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position.

Business Wire 5 months ago

TIVC
-5.06%
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

FREMONT, Calif., November 07, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to b

Business Wire 5 months ago

TIVC
-5.06%
First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

FREMONT, Calif., October 29, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device.

Business Wire 6 months ago

TIVC
-5.06%
Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

SAN FRANCISCO, October 24, 2024--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst’s presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company’s advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation.

Business Wire 6 months ago

TIVC
-5.06%

Performance Overview

Return	TIVC	S&P 500 (^GSPC)
YTD	-33.02%	-3.77%
1-Year	-60.72%	+8.55%
3-Year	-99.86%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tivic Health Systems, Inc. (TIVC)

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Tivic Health Systems, Inc. Announces Reverse Stock Split

Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve

Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

CEO Letter to Shareholders Issued by Tivic Health

Tivic Health Systems Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Tivic hits enrolment target for vagus nerve stimulation trial

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Validates European Patents in Great Britain, Germany, and France

Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

First Subject Enrolled in Tivic Health’s Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health CEO Jennifer Ernst to Present at New York BioFuture 2024

Performance Overview